The respiratory syncytial virus (RSV) commonly causes lung and respiratory tract infections in children. It kills or forces the hospitalization of thousands of babies around the world each year. Mayo Clinic researchers suggest that the virus is so common that most children have been infected with it by age two.
Researchers in Chile revealed that they have developed the first vaccine against the RSV. The team said, "After clinical trials can be held it hopes to market the vaccine against so-called RSV in four or five years."
Respiratory Syncytial Virus Infection Induces Systemic Dysregulation Of Immune Response In Children
Profound systemic dysregulation of the immune response induced by RSV infection in young children reveals a study published this week in PLOS Medicine .
Advertisement
‘The vaccine against the respiratory syncytial virus has been successful in tests with animals and now the research team is ready for clinical trials on people.’
Tweet it Now
In temperate climates like that of Chile, there are annual epidemics of the virus in winter.
After ten years of work the vaccine was developed by a team led by Dr. Alexis Kalergis at the Millennium Institute on Immunology and Immunotherapy.
![Candidate Vaccine Against Respiratory Syncytial Virus Developed]( "Candidate Vaccine Against Respiratory Syncytial Virus Developed")
Respiratory syncytial virus (RSV) is a leading cause of illness and hospitalization among very young children.
"This virus is very harmful and costly for Chilean society and the vast majority of countries," said Kalergis.
Kalergis further added, "The vaccine has been successful in tests with animals and now the team is ready for clinical trials on people. Assuming we have financing and the results are favorable, we could have a vaccine in four or five years."
Source: AFP
Candidate Vaccine Against Respiratory Syncytial Virus Developed
Respiratory syncytial virus (RSV) is a leading cause of illness and hospitalization among very young children.
Advertisement
"This virus is very harmful and costly for Chilean society and the vast majority of countries," said Kalergis.
Kalergis further added, "The vaccine has been successful in tests with animals and now the team is ready for clinical trials on people. Assuming we have financing and the results are favorable, we could have a vaccine in four or five years."
Source: AFP
Respiratory Syncytial Virus - Not as Many Deaths as Previously Thought
Infant deaths from respiratory syncytial virus are quite uncommon in the 21st century, shows new research, although the virus has long been characterized as dangerous and deadly.
Advertisement
 Respiratory Syncytial Virus and Bacterial Pneumonia Share a LinkRecent study has established an association between pneumonia and respiratory syntical virus among children aged 1-2 years. | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
Injury to the white matter explains why football players are at an increased risk for cognitive and behavioral problems later in life.
Located at the South Col, the rocky area between Mount Everest and Lhotse serves as the final campsite for climbers as well as a frozen legacy of hardy microbes.
The new finding is found to be valuable for screening specific medications and treatment against Giardia and other protozoan parasites.
New CRISPR genome-editing strategy was found to have a positive impact in the treatment of inherited retinal diseases such as retinitis pigmentosa.
H3N2 Influenza: The newly developed RT-qPCR Kit to identify influenza, COVID-19 and respiratory virus has got approval from ICMR.